Dostarlimab

• A Phase II, Open-Label, Single Arm, prospective, multicenter study of niraparib plus dostarlimab in patients with pleural mesothelioma posit… Pending
  2024-515555-38-01 Phase II 1 country Universita' Degli Studi Di Torino
• Phase II randomized trial of XELOX plus DoSTARlimab versus XELOX alone as Consolidation Treatment after Standard Chemoradiation in pMMR/MSS … Recruiting
  2024-519798-20-00 Phase II 1 country G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica
• Phase II clinical trial to assess the efficacy of dostarlimab as neoadjuvant therapy in patients with MMRd/MSI-H stage II-III endometrial ca… Recruiting
  2024-512021-81-00 Phase II 1 country Grupo Espanol De Investigacion En Cancer De Ovario
• A Phase I/II study of GSK5733584 in combination with anti-cancer therapies for advanced solid tumors Recruiting
  2024-517147-31-00 Phase I/II 12 countries Glaxosmithkline Research & Development Limited
• Early Phase II Exploratory, Open-Label, Non-Randomized Study of Neoadjuvant Dostarlimab Monotherapy in Participants with Untreated T3-4N0-2 … Recruiting
  2024-512499-36-00 Phase II 1 country UZ Leuven
• PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatel… Recruiting
  2024-510772-20-00 Phase II 1 country Centre Hospitalier Universitaire De Dijon
• A Phase 2, open label, randomized study of neoadjuvant dostarlimab plus CAPEOX versus CAPEOX in participants with previously untreated T4N0 … Recruiting
  2024-513441-36-00 Phase II 3 countries Glaxosmithkline Research & Development Limited
• An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to ch… Recruiting
  2024-516782-36-00 Phase II 3 countries Asso De Recherche Cancers Gynecologiques
• Immunotherapy with dostarlimab for locally advanced or metastatic cancer (non-colorectal/non-endometrial) with tumor dMMR/MSI Recruiting
  2023-505298-34-00 Phase II 1 country Unicancer
• A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un… Recruiting
  2023-508613-17-00 Phase III 13 countries Glaxosmithkline Research & Development Limited
• Akynzeo as antiemetic treatment in patients with endometrial cancer treated with taxane - platinum combination chemotherapy. NOEME study. Recruiting
  2023-504150-35-00 Phase IV 1 country Fondazione IRCCS Istituto Nazionale Dei Tumori
• Watch-and-wait strategy to initiate Dostarlimab-based Immunotherapy in localized deficient mismatch repair (dMMR) and/or microsatellite inst… Recruiting
  2023-506102-39-00 Phase II 2 countries Gercor
• Study aiming to assess the clinical impact of dostarlimab on occurrence of second primary cancer in patients with cured primary cancer Recruiting
  2022-501316-34-00 Phase II 1 country Centre Leon Berard
• Improving public cancer care by implementing precision medicine in Norway Recruiting
  2023-507894-16-00 Phase II 1 country Oslo University Hospital HF
• Induction and maintenance treatment with PARP inhibitor and immunotherapy in HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC). PRI… Recruiting
  2024-516798-54-00 Phase II 1 country Fondazione GONO Plus
• Randomized phase III trial on NIraparib-Dostarlimab vs physician’s choice CHEmotherapy in recurrent, ovarian, fallopian tube or primary peri… Recruiting
  2024-516649-38-00 Phase III 4 countries Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• FTIH study to investigate the safety and preliminary efficacy of the DNA-repair inhibitor GSK4418959 alone or in combination with other anti… Ended
  2024-519721-37-00 Phase I (FiH) 3 countries Glaxosmithkline Research & Development Limited
• A Phase I/IIa Study of Roginolisib in combination with dostarlimab with or without docetaxel in Advanced NSCLC (PULMO-01) Ended
  2024-517741-14-00 Phase I/II 3 countries iOnctura SA
• DOVIPA, a phase II study evaluating efficacy and safety of DOstarlimab and oral VItamin D3 with folinic acid, 5FU, Irinotecan plus oxalipalt… Ended
  2023-510004-49-00 Phase II 1 country Hospital Foch
• A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended
  2023-504753-12-00 Phase III 20 countries Glaxosmithkline Research & Development Limited
• Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic … Ended
  2023-503428-24-00 Phase II 12 countries Glaxosmithkline Research & Development Limited
• Phase 3 study of perioperative dostarlimab in participants with untreated T4N0 or stage III dMMR/MSI-H resectable colon cancer Ended
  2023-503265-27-00 Phase III 14 countries Glaxosmithkline Research & Development Limited
• Phase Ib/II non-randomized non-comparative two-cohort study of Niraparib and Dostarlimab plus (Chemo)RadIotherapy in Locally-Advanced head a… Ended
  2024-516779-33-00 Phase I/II 1 country Grupo Espanol De Tratamiento De Tumores De Cabeza Y Cuello
• Phase 2 Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer Ended
  2023-509583-22-00 Phase II 5 countries Glaxosmithkline Research & Development Limited

Showing 1–24 of 37 trials